Clinical Trial

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-23; most recent amendment 2026-01-26.
Trial Details
NCT Number NCT05305924
Lead Sponsor The Methodist Hospital Research Institute
Collaborators: Eli Lilly and Company
Conditions ER-Positive Breast Cancer, HER2-negative Breast Cancer
Enrollment 28 participants
Start Date 2021-02-25
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-28